Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker (MYC) for predicting cervical lesions occurrence of HPV positive patients

A technology of cervical lesions and biomarkers, applied in the application field of tumor markers in predicting the prognosis of cervical cancer, can solve the problems of low sensitivity, low specificity and sensitivity, missed diagnosis and missed treatment of patients, etc., and achieve a false positive rate Low, sensitive diagnosis or, the effect of reducing the workload

Inactive Publication Date: 2019-08-13
THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, both methods have their own limitations, which affect the effectiveness of screening
The limitations of cervical liquid-based cytology are as follows: (1) low sensitivity. A data covering more than 60,000 people in Europe and North America showed that about half of CIN2, CIN2, and CIN3 and cervical cancer patients often lead to missed diagnosis and treatment of patients; (2) The level of sampling, production and reading of cytological smears is uneven, lacking standardized quality control, and strong subjective dependence
The limitations of high-risk HPV detection are as follows: (1) The lifetime infection risk of high-risk HPV is 80%. Although HPV detection can improve the sensitivity, it cannot distinguish between transient HPV infection and pathogenic persistent infection; (2) Premature women, especially those younger than 30 years old, have a high rate of HPV infection, and the clinical significance is weak
(3) With low specificity and sensitivity, it is easy to cause waste of social medical resources and overdiagnosis and treatment of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker (MYC) for predicting cervical lesions occurrence of HPV positive patients
  • Marker (MYC) for predicting cervical lesions occurrence of HPV positive patients
  • Marker (MYC) for predicting cervical lesions occurrence of HPV positive patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Using immunohistochemical staining to detect the expression of MYC protein in different tissue samples

[0023] Cases: From September 2015 to September 2017, HPV-positive patients who underwent cervical cancer screening at the First Affiliated Hospital of Sun Yat-sen University. Patients were tested for both HPV and LCT, or they had HPV test results from another authoritative medical institution. A total of 243 HPV-positive women were recruited, and samples from 197 eligible subjects who agreed to undergo colposcopy were collected for the study.

[0024] Exclusion criteria: (1) patients with a history of CIN or cervical cancer treatment; (2) patients younger than 30 years old or older than 65 years old; (3) patients who were pregnant or breastfeeding.

[0025] Among the 197 patients who underwent colposcopy, 73 cases were normal, 22 cases were CIN1, 47 cases were CIN2, 51 cases were CIN3, and 4 cases were ICC (the operation process was as follows: figure 1 ...

Embodiment 2

[0040] Example 2. Immunohistochemical method to detect the expression of MYC protein in different cell samples.

[0041] (1) Dewaxing and hydration: put the prepared cell smear in a 60°C incubator and bake for 2 hours, then immerse in xylene 3 times, 5 minutes each time; 2 times in absolute ethanol, 5 minutes each time; In 95%, 85%, and 75% ethanol for 5 minutes each; wash with PBS 3 times, 5 minutes each time.

[0042] (2) Eliminate endogenous peroxidase: Remove the liquid around the tissue on the smear, place it flat in a wet box, add 3% hydrogen peroxide solution dropwise, incubate at room temperature for 10-15 minutes, wash with PBS 3 times, 5 minutes each time .

[0043] (3) Antigen retrieval: Put the smear into citrate buffer, put it into a pressure cooker and heat it to boiling, 800w, cover the pressure valve and wait for 1-4 minutes after spraying. The temperature of the buffer was naturally cooled to room temperature, and washed 3 times with PBS (containing Triton X...

Embodiment 3

[0053] Example 3 Verifies the correlation between MYC gene and human papillomavirus positive patients

[0054] The corresponding MYC protein expression levels in different stages of cervical lesions (normal, CIN1, CIN2, CIN3 and invasive cancer) in the aforementioned cases of cervical lesions were analyzed to obtain the frequency and proportion of MYC staining intensity at different stages. The results are shown in Table 1:

[0055] Table 1: Frequency and proportion of staining intensity of MYC in different stages of cervical lesions

[0056]

[0057]

[0058] CIN = cervical intraepithelial neoplasia; ICC = invasive cervical cancer

[0059] It can be seen from Table 1 that MYC staining was positive in CIN2+ tissues and negative in CIN1- tissues, indicating that the trend of MYC expression intensity was positively correlated with the severity of cervical disease.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a marker (MYC) for predicting the cervical lesions occurrence of HPV positive patients. The biomarker is an MYC gene or protein encoded by the MYC gene, and the amino acid sequence of the biomarker is shown as SEQ NO.1. The biomarker has an HPV integration site. The biomarker can assist doctors in diagnosing the cervix uteri high-grade intraepithelial neoplasia conditions of the human papilloma virus positive patients or screen out precancerous lesions patients with the risk of the progress to the cervical cancer for emphatic monitoring. The biomarker which detects thehigh risk group of the human papilloma virus positive patients has the advantages of being rapid, accurate, convenient to use, low in false positive rate and the like and has important clinical diagnosis significance.

Description

technical field [0001] The invention relates to the field of tumor molecular biology, in particular to the application of a tumor marker in predicting the prognosis of cervical cancer. Background technique [0002] Cervical cancer is one of the most common gynecological malignancies worldwide, ranking fourth among female malignancies in both morbidity and mortality. According to reports, there are about 528,000 new cases of cervical cancer in the world every year, and more than 265,000 deaths per year. The annual new cases in developed countries and developing countries are 83,000 and 445,000, respectively, and the annual deaths are 35,000 and 230,000. , about 87% of cervical cancer deaths occur in developing countries. In my country, the incidence of cervical cancer ranks first among female reproductive tract tumors. There are more than 130,000 new cases of cervical cancer every year, accounting for about 1 / 3 of the total number of new cases of cervical cancer in the world...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/68G01N33/574
CPCC12Q1/6886C12Q2600/136C12Q2600/158G01N33/57411G01N33/57484G01N33/68G01N2333/4703
Inventor 胡争杨帆田瑞樊惟文崔资凤金庄
Owner THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com